Treatment compliance at initial and maintenance therapy at gastroesophageal reflux disease

Aim of investigation. To analyze treatment compliance at initial course and maintenance treatment by proton pump inhibitors at gastroesophageal reflux disease (GERD). Material and methods. Overall 84 GERD patients with took part in prospective study: 50 (59.5%) men and 34 (40.5%) women aged from 18 to 74 years. By results of esophagogastroduodenoscopy and morphological investigation of mucosal biopsies non-erosive reflux disease (NERD) was diagnosed in 32 (38.1%) patients, reflux esophagitis was found in 52 cases (61.9%). Total period of patients monitoring was 12 months at which patients made five visits to the research center: initial, through 1.5, 3, 6 and 12 months with filling in of questionnaires of Spielberger-Khanin, Beck, SF-36 and abridged multifactorial questionnaire of the personality (AMQP). Treatment compliance was established according to duration of study participation, along with that patients self-estimated it on 2, 3, 4 and 5 visits by Morisky-Green test and 5-score analog scales of pharmaceutical treatment compliance and lifestyle verification. The first visit patients underwent 1:1 randomization to the educational program devoted to reflux disease. Results. Of all patients 17.9% missed the second visit, the logistic regression analysis revealed no factors associated to the early low compliance; 38% of patients made all five visits for 12 months. The latter differed significantly from those who dropped out of the study at different stages: they had high number of chronic diseases (р<0.01), received higher quantity of drugs on the constant basis (р<0.01), got lower scores by the paranoid trait scale of AMQP (р<0.05). Logistic regression is revealed factors associated to the low level of treatment compliance: number of chronic concomitant diseases (OR=1.64; р=0.0033), quantity of the received drugs (OR=1.63; р=0.0158), scores by paranoid trait AMQP scale (OR=0.95; р=0.042). Conclusion. Single course educational program in GERD patients increases treatment compliance for initial course while does not affect maintenance therapy compliance. Following predictors of high treatment motivation were found: existence of chronic diseases and intake of medications on the regular basis for concomitant diseases, minimal intensity of rigidity of affect personality trait. Constant maintenance therapy is optimal for GERD patients in the Russian population, at the same time in NERD patients without low compliance markers the course maintenance therapy can be applied.

гастроэзофагеальная рефлюксная болезнь, приверженность к лечению, ингибиторы протонной помпы, образовательная программа, поддерживающая терапия

1. Tytgat G. N., McColl K., Tack J., et al. New algorithm for the treatment of gastroesophageal reflux. Aliment Pharmacol Ther 2008; 27(3):249-56.

2. Vakil N., van Zanten S. V., Kahrilas P., et al. Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101(8):1900-20.

3. Лазебник Л. Б., Машарова А. А., Бордин Д. С. и др. Многоцентровое исследование «Эпидемиология гастроэзофагеальной рефлюксной болезни в России (МЭГРЕ): первые итоги. Эксперим клин гастроэнтерол 2009; 6:4-12.

4. Dent J., El-Serag H.B., Wallander M. A., et al. Epidemiology of gastroesophageal reflux disease: a systematic review. Gut 2007; 54(5):710-17.

5. Kulig M., Leodolter A., Vieth M., et al. Quality of life in relation to symptoms in patients with gastroesophageal reflux disease - an analysis based on the. Aliment Pharmacol Ther 2003; 18(8):767-76.

6. Adherence to long-term therapies: evidence for action [Электронный ресурс]. World Health Organisation 2003. URL: http://www.who.com/ int2 (Дата обращения: 18.08.2013).

7. McDonnell P.J., Jacobs M. R. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36(9):1331-6.

8. Haynes R. B., McDonald H., Garg A. X., et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. Ontario: McMaster University Medical Centre, 2008.345 p.

9. Dukat A, Balazovjech I. A 5-year follow-up of preventive aproach to patients with essential hypertension. J Hum Hypertension 1996; 10:131-3.

10. Van Soest E. M., Siersema P. D., Dieleman J. P., et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006; 24(2):377-85.

11. Claxton A. J., Cramer J., Pierce C. A. Systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23(8):1296-310.

12. Tsai H. H., Chapman R., Shepherd A., et al. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopynegative gastroesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004; 20(6):657-65.

13. Steven I. D., Wing L. Control and cardiovascular risk factors of hypertension. An assessment of a sample of patients. Aus Fam Physician 1999; 28:45-8.

14. Williams M. V., Baker D. W., Parker R. M., et al. Relationship of functional Health literacy to patients’ knowledge of their chronic disease. A study of patients with hypertension and diabetes. Arch Intern Med 1998; 158:166-72.